{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kwon D"],"funding":["Terry Fox Research Institute","Canadian Institutes for Health Research","CIHR"],"pagination":["1628-1639"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9365342"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(8)"],"pubmed_abstract":["<h4>Purpose</h4>Mantle cell lymphoma (MCL) is associated with poor survival. The purpose of this study was to assess whether the C-X-C chemokine receptor type 4 (CXCR4) is a useful target for imaging and radioligand therapy of MCL, using a novel pair of radioligands, [68Ga]Ga and [177Lu]Lu-BL02.<h4>Experimental design</h4>We performed a retrospective analysis of 146 patients with MCL to evaluate CXCR4 expression and its correlation with outcomes. Guided by in silico methods, we designed BL02, a new radioligand labelled with 68Ga or 177Lu for PET imaging and therapy, respectively. We performed imaging and biodistribution studies in xenograft models with varying CXCR4 expression. We evaluated [177Lu]Lu-BL02 in MCL models, and evaluated its potential for therapy in Z138 MCL xenografts.<h4>Res"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands."],"pmcid":["PMC9365342"],"funding_grant_id":["FDN-148465","1061"],"pubmed_authors":["Chong L","Rousseau J","Merkens H","Benard F","Fraser B","Kwon D","Miyata-Takata T","Steidl C","Zhang Z","Lau J","Kuo HT","Takata K","Aoki T","Villa D","Zeisler J","Zhang C","Lin KS","Tan R","Uribe CF"],"additional_accession":[]},"is_claimable":false,"name":"Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.","description":"<h4>Purpose</h4>Mantle cell lymphoma (MCL) is associated with poor survival. The purpose of this study was to assess whether the C-X-C chemokine receptor type 4 (CXCR4) is a useful target for imaging and radioligand therapy of MCL, using a novel pair of radioligands, [68Ga]Ga and [177Lu]Lu-BL02.<h4>Experimental design</h4>We performed a retrospective analysis of 146 patients with MCL to evaluate CXCR4 expression and its correlation with outcomes. Guided by in silico methods, we designed BL02, a new radioligand labelled with 68Ga or 177Lu for PET imaging and therapy, respectively. We performed imaging and biodistribution studies in xenograft models with varying CXCR4 expression. We evaluated [177Lu]Lu-BL02 in MCL models, and evaluated its potential for therapy in Z138 MCL xenografts.<h4>Res","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-07-14T21:12:25.144Z","creation":"2024-11-20T21:02:47.155Z"},"accession":"S-EPMC9365342","cross_references":{"pubmed":["35078860"],"doi":["10.1158/1078-0432.CCR-21-3284"]}}